Verastem stock rises after LGSOC treatment data published in medical journal

Investing.com -- Verastem Inc (NASDAQ:VSTM) stock gained 3.5% after the company announced that primary analysis data from its Phase 2 RAMP 201 clinical trial was published in the Journal of Clinical Oncology.

The published data showed that the combination of avutometinib plus defactinib demonstrated a confirmed overall response rate of 31% in all patients with recurrent low-grade serous ovarian cancer (LGSOC). The response rate was notably higher at 44% in patients with KRAS mutations compared to 17% in those with KRAS wild-type.

The findings supported the recent FDA approval of the combination therapy for KRAS-mutated recurrent LGSOC. Verastem plans to submit the publication to the National Comprehensive Cancer Network in support of including the KRAS wild-type population in clinical practice guidelines.

"The majority of patients (82%) had some reduction in target lesions, regardless of KRAS mutation status," according to the published results. The median duration of response was 31.1 months for all patients and the same for the KRAS mutant population, while median progression-free survival was 12.9 months for all patients and 22.0 months in the KRAS mutant population.

Professor Susana Banerjee, Global Lead Principal Investigator of the trial, noted that the combination demonstrated "clinically meaningful and durable responses" and highlighted its "potential to be the new standard of care in recurrent low-grade serous ovarian cancer."

The treatment was reported to be well-tolerated, with only 10% of patients discontinuing due to adverse events. Common side effects included nausea, diarrhea, and increased creatine phosphokinase levels.

Verastem is currently conducting a global Phase 3 RAMP 301 trial evaluating the combination in recurrent LGSOC patients with and without KRAS mutations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.